Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Sep - Newspaper Advertisement regarding transfer of Shares to IEPF and Notice of loss of share Certificate
Source: Bse
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)
Small CapPharma stocks · Small cap · NSE
Jagsonpal Pharmaceuticals Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result29 Jul, 10:49 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
66BullishSMA20 -2.8% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 44
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
JAGSNPHARMD candles · FIT view+7.0%Latest close ₹217.91 on 2026-10-21
Bar
-0.6%
RSI
36
MACD hist
-1.53
52W pos
57%
2026-10-21O ₹219.30H ₹222.22L ₹210.01C ₹217.91Vol 79,054 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
JAGSNPHARMNifty PharmaNifty 500
- JAGSNPHARM
- -1.9%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +4.6 pp
Chart stats
21 Oct 2026- From 52W high
- -17.6%
- 52W range position
- 57%
- ATR (14)
- 4.0%
- Volume vs 20D
- 0.13x
- Avg traded value
- ₹14.3 Cr
- 20D price channel
- ₹210 - ₹251
₹264.5
₹155 - ₹264.5
₹8.7
Latest completed session
20-session average
36.0% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE58
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good70
Revenue +7.9% · PAT +18.2% YoY
Technical
Bullish66
Price trend and sector-relative-strength timing.
Valuation
Legacy model+29.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence80
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 70/100Rev +8% YoY · PAT +18% YoY · margin expansion · +28% QoQ · operating leverage
Filed 29 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹82 Cr | +7.9% | +28.1% |
| EBITDA | ₹17 Cr | +21.4% | +54.5% |
| Operating margin | 21.0% | +200 bps | +400 bps |
| PAT | ₹13 Cr | +18.2% | +44.4% |
| PAT margin | 15.8% | +138 bps | +179 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 32.20
- P/B
- 5.56
- EV/EBITDA
- 21.74
- Market Cap
- 1514.00Cr
Profitability
- ROE
- 17.30%
- ROCE
- 22.70%
- ROA
- 14.20%
- Dividend Y
- 1.74%
Growth (CAGR)
- Revenue 5Y
- 9.00%
- EPS 5Y
- 21.00%
- Revenue 3Y
- 7.00%
- EPS 3Y
- 16.00%
Balance Sheet
- Debt/Equity
- 0.03
- Interest Coverage
- 61.00×
- Altman Z
- 9.04
- Book Value
- 41.20
Cash Flow
- FCF Yield
- 0.73%
- FCF Positive Y
- 8/5
- OCF
- 47.00 Cr
- EPS TTM
- 6.84
Shareholding
- Promoter Hold
- 69.06%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 67%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 82.0+28.1% vs prev
Net Profit
₹ CrLatest: 13.0+44.4% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 36.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~2.9% over last month) — short-term momentum negative.
- RSI(14) at 36 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 18% off 52W high · 41% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
68
RS percentile
Stage 1 Base / Transition
1M return
-3.9%
3M return
-1.9%
6M return
+7.9%
1Y return
-2.0%
RS 1D
+3
RS 20D
+6
Sector rank
#1
Industry rank
#9
Stage evidence
- Price is within 0.1% of the 30-week proxy.
- The 30-week proxy changed +3.4% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 103.61+1.04%
RS vs Nifty 500104
Valuation & peers
U-Score 58 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 58 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation7/30
Growth16/25
Quality13/20
Balance Sheet12/15
Cash Flow5/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
58
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
58/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 29.2%.
- Balance sheet contributes 12/15 to the score.
Main drags
- Valuation is weaker at 7/30; verify the latest quarterly trend.
- Cash flow is weaker at 5/10; verify the latest quarterly trend.
- Growth is weaker at 16/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
32.2
PB
5.6
EV/EBITDA
21.7
ROE
17.3%
ROCE
22.7%
FCF Yield
0.7%
Debt/Equity
0.0
MoS
+29.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
58
Previous: 58
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+29.2%
Previous: +29.3%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
58
58
58
58
58
58
58
58
58
58
58
58
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹79.63
-173.7% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹307.8
+29.2% MoS
PEG
1.69
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
ANUHPHR
Small
Anuh Pharma Limited
Pharmaceuticals
match 166
40
19.5
10.7%
+40%
WATCHLIST
AHCL
Small
Anlon Healthcare Limited
Pharmaceuticals
match 166
41
52.5
18.4%
-11%
WATCHLIST
BAFNAPH
Small
Bafna Pharmaceuticals Limited
Pharmaceuticals
match 165
27
—
-6.2%
—
OVERVALUED
KOPRAN
Small
Kopran Limited
Pharmaceuticals
match 164
22
51.9
4.9%
-1785%
OVERVALUED
WINDLAS
Small
Windlas Biotech Limited
Pharmaceuticals
match 163
49
31.6
12.2%
+36%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Jagsonpal Pharmaceuticals Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
80Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 90th percentile of the scored universe and 87th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
62 docs text-extracted · 13 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
90th percentile
overall median 67 · Pharma: 87th pctile, median 70 · Small: 92nd pctile, median 66
Evidence depth
Financial-only
62 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
90
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
74
acceptable · capital discipline
Results
60
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 69.1%.
- ▸Promoter pledge is zero.
- ▸Promoter holding increased 1.5%.
- ▸FCF yield is positive at 0.7%.
Trust risks
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Jagsonpal Pharmaceuticals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 30 Sep - Allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 23 Sep - Jagsonpal signs BTA to acquire Group Pharma’s Wellness Portfolio for ₹23.7 crore, up to ₹46.7 crore total.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Aug - Newspaper Publication for dispatch of Notice of 47th Annual General Meeting, Annual Report 2025-26 and e-voting
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.